Jade Biosciences, Inc.
JBIO•NASDAQ•Healthcare•Biotechnology

About Jade Biosciences

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. The company develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. It also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOTom Frohlich
Founded2024
Employees30
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitejadebiosciences.com
Phone781 312 3013
Address
Building 23, Suite 105 Waltham, Massachusetts 02453 United States

Corporate Identifiers

CIK0000947559
CUSIP008064206
ISINUS0080642061
EIN64-0862173
SIC6021

Leadership Team & Key Executives

Tom Frohlich
Chief Executive Officer and Director
Bradford D. Dahms Ph.D.
Chief Financial Officer and Treasurer
Dr. Andrew James King D.V.M., Ph.D.
Chief Scientific Officer and Head of Research & Development
Elizabeth Balta J.D.
General Counsel and Corporate Secretary
Lori Stewart
Senior Vice President of People
Dr. Jason Wright Ph.D.
Senior Vice President of Chemistry, Manufacturing and Controls
Jonathan Quick
Senior Vice President of Finance
Valerie Fauvelle
Senior Vice President of Regulatory and Quality
Amy Sullivan
Senior Vice President of Development Operations
Sandy Lewis
Senior Vice President, Biometrics and Clinical Strategy